Yüklüyor......
Tailoring front-line therapy in diffuse large B-cell lymphoma: who should we treat differently?
Although there have been significant insights into the biology of diffuse large B-cell lymphoma (DLBCL) over recent years, progress in our therapeutic approach has been disappointing over the same timeframe. This is not for want of trying. In 2017, R-CHOP (rituximab plus cyclophosphamide, doxorubici...
Kaydedildi:
| Yayımlandı: | Hematology Am Soc Hematol Educ Program |
|---|---|
| Yazar: | |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
American Society of Hematology
2017
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6142538/ https://ncbi.nlm.nih.gov/pubmed/29222268 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|